WO2012026907A3 - Cefpodoxime proxetil formulations - Google Patents

Cefpodoxime proxetil formulations Download PDF

Info

Publication number
WO2012026907A3
WO2012026907A3 PCT/TR2011/000200 TR2011000200W WO2012026907A3 WO 2012026907 A3 WO2012026907 A3 WO 2012026907A3 TR 2011000200 W TR2011000200 W TR 2011000200W WO 2012026907 A3 WO2012026907 A3 WO 2012026907A3
Authority
WO
WIPO (PCT)
Prior art keywords
formulations
cefpodoxime proxetil
proxetil
cefpodoxime
relates
Prior art date
Application number
PCT/TR2011/000200
Other languages
French (fr)
Other versions
WO2012026907A2 (en
Inventor
Mahmut Bilgic
Original Assignee
Mahmut Bilgic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mahmut Bilgic filed Critical Mahmut Bilgic
Priority to EP11782258.5A priority Critical patent/EP2608776A2/en
Publication of WO2012026907A2 publication Critical patent/WO2012026907A2/en
Publication of WO2012026907A3 publication Critical patent/WO2012026907A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Abstract

The present invention relates to pharmaceutical formulations comprising cefpodoxime proxetil.
PCT/TR2011/000200 2010-08-25 2011-08-24 Cefpodoxime proxetil formulations WO2012026907A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP11782258.5A EP2608776A2 (en) 2010-08-25 2011-08-24 Cefpodoxime proxetil formulations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2010/07106 2010-08-25
TR2010/07106A TR201007106A1 (en) 2010-08-25 2010-08-25 Cefpodoxime proxetil formulations.

Publications (2)

Publication Number Publication Date
WO2012026907A2 WO2012026907A2 (en) 2012-03-01
WO2012026907A3 true WO2012026907A3 (en) 2012-09-13

Family

ID=44947169

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2011/000200 WO2012026907A2 (en) 2010-08-25 2011-08-24 Cefpodoxime proxetil formulations

Country Status (3)

Country Link
EP (1) EP2608776A2 (en)
TR (1) TR201007106A1 (en)
WO (1) WO2012026907A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103142506B (en) * 2013-04-03 2015-02-25 天津医药集团津康制药有限公司 Cefpodoxime proxetil granules and preparation method thereof
CN103230367B (en) * 2013-05-07 2014-11-12 山东罗欣药业集团股份有限公司 Cefpodoxime proxetil composition dry suspension and preparation method thereof
CN107693491B (en) * 2017-04-20 2020-06-30 广东金城金素制药有限公司 Pharmaceutical composition and preparation for children
CN108815130A (en) * 2018-08-27 2018-11-16 邓倩 A kind of Cefpodoxime Proxetil tablet and its production technology

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002067943A1 (en) * 2001-02-27 2002-09-06 Ranbaxy Laboratories Limited Oral pharmaceutical composition of cefpodoxime proxetil
WO2004004737A1 (en) * 2002-07-08 2004-01-15 Sankyo Company, Limited Cephalosporin preparation for oral use
WO2004006917A1 (en) * 2002-07-16 2004-01-22 Ranbaxy Laboratories Limited Dispersible tablets for oral administration
WO2007017895A2 (en) * 2005-05-05 2007-02-15 Lupin Limited Stabilized oral pharmaceutical compositions of cephalosporins
WO2011129792A1 (en) * 2010-04-13 2011-10-20 Mahmut Bilgic Water dispersible formulations comprising cefpodoxime proxetil

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4486425A (en) 1980-09-30 1984-12-04 Sankyo Company Limited 7-[2-(2-Aminothiazol-4-yl)-2-(syn)-methoxyiminoacetamido]-3-methoxymethyl-3-cephem-4-carboxylates

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002067943A1 (en) * 2001-02-27 2002-09-06 Ranbaxy Laboratories Limited Oral pharmaceutical composition of cefpodoxime proxetil
WO2004004737A1 (en) * 2002-07-08 2004-01-15 Sankyo Company, Limited Cephalosporin preparation for oral use
WO2004006917A1 (en) * 2002-07-16 2004-01-22 Ranbaxy Laboratories Limited Dispersible tablets for oral administration
WO2007017895A2 (en) * 2005-05-05 2007-02-15 Lupin Limited Stabilized oral pharmaceutical compositions of cephalosporins
WO2011129792A1 (en) * 2010-04-13 2011-10-20 Mahmut Bilgic Water dispersible formulations comprising cefpodoxime proxetil

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 200416, Derwent World Patents Index; AN 2004-169094, XP002676813 *

Also Published As

Publication number Publication date
EP2608776A2 (en) 2013-07-03
WO2012026907A2 (en) 2012-03-01
TR201007106A1 (en) 2012-03-21

Similar Documents

Publication Publication Date Title
JOP20180102B1 (en) Pharmaceutical composition
MX340831B (en) Pesticidal compositions.
WO2011093824A3 (en) Effervescent formulations comprising cefaclor
PT2591091E (en) Method for the preparation of 1,3-propanediol from sucrose
WO2012137227A3 (en) Solid forms of antiretroviral compounds and anti-oxidative acids, processes for preparation and pharmaceutical compositions thereof
WO2012064743A3 (en) Methods for improving heart function
WO2012026907A3 (en) Cefpodoxime proxetil formulations
WO2012080176A3 (en) Pharmaceutical compositions comprising alisporivir
WO2012060786A3 (en) Cefpodoxime proxetil formulations comprising viscosity agent
WO2012051126A3 (en) Anti-inflammatory macrolides
TR201002878A2 (en) Pharmaceutical compositions comprising cefpodoxime proxetil.
ZA201300285B (en) Disconnector,particularly of the double-break double-movement type
WO2012007570A3 (en) New formulations of 14-epi-analogues of vitamin d
ITTO20110857A1 (en) PROCEDURE FOR THE PRODUCTION OF CYCLOHEXANONOSSIN.
WO2012004073A3 (en) Use of beta-isophorone as solvent
WO2011152805A3 (en) Pharmaceutical composition comprising cefpodoxime proxetil and clavulanic acid
EP2481097A4 (en) Photodiode of the type avalanche photodiode
WO2011042077A8 (en) Transdermal therapeutic systems containing 4-n-butylresorcinol
WO2012026908A3 (en) Cefpodoxime proxetil formulations comprising taste regulating agent
WO2013081563A3 (en) Stable voglibose tablet formulations
IN2014DN05954A (en)
AU2012900169A0 (en) Translations by the Hour
TN2013000218A1 (en) Pharmaceutical compositions comprising alisporivir
AU2010904996A0 (en) Pharmaceutical compositions
AU2010904478A0 (en) ozfill.com

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11782258

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011782258

Country of ref document: EP